United Therapeutics Achieves Breakthrough in Drug Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy UTHR?
Source: NASDAQ.COM
- Clinical Trial Success: United Therapeutics' long-term Phase 3 ADVANCE OUTCOMES study of ralinepag in pulmonary arterial hypertension met its primary endpoint, reducing the risk of clinical worsening by 55% compared to placebo, indicating significant efficacy and potential new treatment options for patients.
- Patient Background Analysis: Among the trial participants, 80% were on dual background therapy and 70% were classified as World Health Organization/New York Heart Association Functional Class II at baseline, suggesting the drug's applicability across various stages of the disease and enhancing its market potential.
- Future Plans: The company intends to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026, which, if approved, would provide a new treatment option for pulmonary arterial hypertension patients and further expand its product line.
- Market Reaction: United Therapeutics' shares closed at $503.90 on Friday, up 0.06%, reflecting market optimism regarding the progress of its drug development, which may drive future stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UTHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UTHR
Wall Street analysts forecast UTHR stock price to fall
8 Analyst Rating
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 571.350
Low
423.00
Averages
534.50
High
645.00
Current: 571.350
Low
423.00
Averages
534.50
High
645.00
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
United Therapeutics (UTHR.US) Officer Plans to Sell $108.56 Million in Common Stock via Form 144
Stock Sale Announcement: Martin Rothblatt intends to sell 190,000 shares of United Therapeutics (UTHR) common stock on May 1, with a total market value of approximately $108.56 million.
Reduction in Shareholding: Rothblatt has reduced his shareholding in United Therapeutics by 408,580 shares since March 2, 2026, with a total value of around $224.88 million.
See More
Joby Aviation Leads eVTOL Commercial Operations in Dubai
- Intensifying Market Competition: Joby Aviation is set to launch commercial eVTOL operations in Dubai in partnership with Uber, marking the beginning of a new era in eVTOL travel despite regional conflict risks, highlighting the sector's potential and attractiveness.
- Diverse Business Models: Joby is pursuing a vertically integrated Transportation-as-a-Service (TaaS) model, combining its own technology with Uber's transportation services, leading the FAA certification race ahead of rivals Archer and Vertical, showcasing its competitive edge.
- Emerging Investment Opportunities: Although eVTOL stocks have sharply declined this year, the long-term potential is evident, with Joby viewed as having the highest upside potential due to its first-mover advantage and TaaS model, attracting investor interest.
- Beta's Market Outlook: Beta Technologies is projected to end 2026 with $971 million in net cash and no need for funding until 2030, making it an attractive option for eVTOL investors due to its reliance on the cargo market and collaboration with Embraer.
See More
Joby Aviation Aims to Lead eVTOL Launches in Dubai
- Market Leadership: Joby Aviation, in partnership with Uber, plans to launch commercial electric vertical takeoff and landing (eVTOL) operations in Dubai in 2023, positioning itself as the frontrunner among Western companies, and despite regional conflicts posing risks, this initiative symbolizes the dawn of a new era in eVTOL travel.
- Competitive Landscape: Joby's rival, Archer Aviation, aims to launch its eVTOL services in Abu Dhabi in 2026; however, Joby is leading the FAA certification race with its ambitious vertically integrated transportation-as-a-service (TaaS) model, highlighting its business model's potential and ambition.
- Technological Investment: Joby is developing its own technology in collaboration with key investor Toyota while establishing a transportation services company through its partnership with Uber, showcasing its strategic positioning in the eVTOL market, even as it faces intense competition from Boeing's Wisk.
- Industry Outlook: Although eVTOL stocks have experienced significant volatility this year, Joby demonstrates considerable long-term growth potential due to its TaaS model and first-mover advantage, yet its future growth plans may require additional funding to sustain momentum.
See More
Analysis of IJK Stock's 52-Week High and Low Points
- Price Fluctuation Analysis: IJK's 52-week low is $80.94 and high is $111.58, with the latest trade at $109.03, indicating significant price movement within this range, reflecting market interest and investor sentiment towards the stock.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides valuable insights for investors, aiding in the assessment of price trends and potential buy or sell opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for assessment of their impact on underlying assets and market dynamics.
See More
United Therapeutics Unveils New Data on Pulmonary Hypertension Studies
- Data Presentation: United Therapeutics will present 11 new data sets at the 2026 ISHLT Annual Meeting, focusing on early detection and management of pulmonary hypertension (PH) and interstitial lung disease (ILD), highlighting the critical role of early intervention in improving patient outcomes.
- Significant Treatment Effects: The interim analysis from the ARTISAN study indicates that high-dose treprostinil treatment significantly reduces mean pulmonary artery pressure (mPAP), improves right heart function, and reverses cardiac remodeling in pulmonary arterial hypertension (PAH) patients, potentially reshaping treatment strategies.
- Innovative Technology Utilization: The research includes machine-learning-based prediction techniques for donor lung acceptance, showcasing how artificial intelligence can enhance lung transplant success rates during ex vivo lung perfusion (EVLP), reflecting the company's extensive commitment to scientific innovation.
- Future Outlook: United Therapeutics is dedicated to addressing the shortage of transplantable organs through innovative therapies and breakthroughs in organ manufacturing, demonstrating its mission as a public benefit corporation to provide better treatment options for patients while creating long-term shareholder value.
See More
Morgan Stanley Raises United Therapeutics Price Target to $519
- Price Target Adjustment: Morgan Stanley analyst Terence Flynn raised the price target for United Therapeutics (UTHR) from $471 to $519, reflecting an optimistic outlook on the company's future performance while maintaining an Equal Weight rating, indicating a cautious market sentiment regarding its stock price.
- Model Updates: This adjustment is based on an analysis of IQVIA trends and intra-quarter updates, suggesting that analysts are considering the latest market dynamics and data to more accurately forecast the company's performance in the biopharma sector.
- Market Reaction: With the price target increase, market attention on United Therapeutics may rise, prompting investors to reassess their portfolios in the biopharma space, which could influence stock price volatility.
- Industry Outlook: In the context of United Therapeutics receiving RMAT (Regenerative Medicine Advanced Therapy) designation from the FDA, market expectations for its future products are heightened, potentially driving further growth in the biopharma market.
See More
United Therapeutics (UTHR.US) Officer Plans to Sell $108.56 Million in Common Stock via Form 144
Stock Sale Announcement: Martin Rothblatt intends to sell 190,000 shares of United Therapeutics (UTHR) common stock on May 1, with a total market value of approximately $108.56 million.
Reduction in Shareholding: Rothblatt has reduced his shareholding in United Therapeutics by 408,580 shares since March 2, 2026, with a total value of around $224.88 million.
See More
Joby Aviation Leads eVTOL Commercial Operations in Dubai
- Intensifying Market Competition: Joby Aviation is set to launch commercial eVTOL operations in Dubai in partnership with Uber, marking the beginning of a new era in eVTOL travel despite regional conflict risks, highlighting the sector's potential and attractiveness.
- Diverse Business Models: Joby is pursuing a vertically integrated Transportation-as-a-Service (TaaS) model, combining its own technology with Uber's transportation services, leading the FAA certification race ahead of rivals Archer and Vertical, showcasing its competitive edge.
- Emerging Investment Opportunities: Although eVTOL stocks have sharply declined this year, the long-term potential is evident, with Joby viewed as having the highest upside potential due to its first-mover advantage and TaaS model, attracting investor interest.
- Beta's Market Outlook: Beta Technologies is projected to end 2026 with $971 million in net cash and no need for funding until 2030, making it an attractive option for eVTOL investors due to its reliance on the cargo market and collaboration with Embraer.
See More
Joby Aviation Aims to Lead eVTOL Launches in Dubai
- Market Leadership: Joby Aviation, in partnership with Uber, plans to launch commercial electric vertical takeoff and landing (eVTOL) operations in Dubai in 2023, positioning itself as the frontrunner among Western companies, and despite regional conflicts posing risks, this initiative symbolizes the dawn of a new era in eVTOL travel.
- Competitive Landscape: Joby's rival, Archer Aviation, aims to launch its eVTOL services in Abu Dhabi in 2026; however, Joby is leading the FAA certification race with its ambitious vertically integrated transportation-as-a-service (TaaS) model, highlighting its business model's potential and ambition.
- Technological Investment: Joby is developing its own technology in collaboration with key investor Toyota while establishing a transportation services company through its partnership with Uber, showcasing its strategic positioning in the eVTOL market, even as it faces intense competition from Boeing's Wisk.
- Industry Outlook: Although eVTOL stocks have experienced significant volatility this year, Joby demonstrates considerable long-term growth potential due to its TaaS model and first-mover advantage, yet its future growth plans may require additional funding to sustain momentum.
See More
Analysis of IJK Stock's 52-Week High and Low Points
- Price Fluctuation Analysis: IJK's 52-week low is $80.94 and high is $111.58, with the latest trade at $109.03, indicating significant price movement within this range, reflecting market interest and investor sentiment towards the stock.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides valuable insights for investors, aiding in the assessment of price trends and potential buy or sell opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding for ETFs helps identify those experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for assessment of their impact on underlying assets and market dynamics.
See More
United Therapeutics Unveils New Data on Pulmonary Hypertension Studies
- Data Presentation: United Therapeutics will present 11 new data sets at the 2026 ISHLT Annual Meeting, focusing on early detection and management of pulmonary hypertension (PH) and interstitial lung disease (ILD), highlighting the critical role of early intervention in improving patient outcomes.
- Significant Treatment Effects: The interim analysis from the ARTISAN study indicates that high-dose treprostinil treatment significantly reduces mean pulmonary artery pressure (mPAP), improves right heart function, and reverses cardiac remodeling in pulmonary arterial hypertension (PAH) patients, potentially reshaping treatment strategies.
- Innovative Technology Utilization: The research includes machine-learning-based prediction techniques for donor lung acceptance, showcasing how artificial intelligence can enhance lung transplant success rates during ex vivo lung perfusion (EVLP), reflecting the company's extensive commitment to scientific innovation.
- Future Outlook: United Therapeutics is dedicated to addressing the shortage of transplantable organs through innovative therapies and breakthroughs in organ manufacturing, demonstrating its mission as a public benefit corporation to provide better treatment options for patients while creating long-term shareholder value.
See More
Morgan Stanley Raises United Therapeutics Price Target to $519
- Price Target Adjustment: Morgan Stanley analyst Terence Flynn raised the price target for United Therapeutics (UTHR) from $471 to $519, reflecting an optimistic outlook on the company's future performance while maintaining an Equal Weight rating, indicating a cautious market sentiment regarding its stock price.
- Model Updates: This adjustment is based on an analysis of IQVIA trends and intra-quarter updates, suggesting that analysts are considering the latest market dynamics and data to more accurately forecast the company's performance in the biopharma sector.
- Market Reaction: With the price target increase, market attention on United Therapeutics may rise, prompting investors to reassess their portfolios in the biopharma space, which could influence stock price volatility.
- Industry Outlook: In the context of United Therapeutics receiving RMAT (Regenerative Medicine Advanced Therapy) designation from the FDA, market expectations for its future products are heightened, potentially driving further growth in the biopharma market.
See More
